Your session is about to expire
← Back to Search
Dietary Supplement
AC-11 for Aging
Phase 2
Waitlist Available
Led By Phillip Gallegos
Research Sponsored by TruDiagnostic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in epigenetic age from baseline to 6 months
Awards & highlights
Study Summary
This trial will study the effects of AC-11 on 24 patients over 6 months to see if it can reverse epigenetic markers of aging.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change in epigenetic age from baseline to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in epigenetic age from baseline to 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Methylation age clock testing
Telomere Test
Trial Design
1Treatment groups
Experimental Treatment
Group I: AC-11Experimental Treatment1 Intervention
6 months of treatment with AC-11
Find a Location
Who is running the clinical trial?
TruDiagnosticLead Sponsor
11 Previous Clinical Trials
454 Total Patients Enrolled
8 Trials studying Aging
344 Patients Enrolled for Aging
Optigenex, IncUNKNOWN
Phillip GallegosPrincipal InvestigatorThrive Medicine Clinic
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Share this study with friends
Copy Link
Messenger